See the DrugPatentWatch profile for Carfilzomib
When does the carfilzomib patent expire in Europe?
I can’t answer the exact expiry date from the information provided here. Patent lifetimes in Europe depend on the specific legal rights involved (the “main” patent, any Supplementary Protection Certificate (SPC), and the expiry of related national/European patents), and the outcome can differ by country and by product/indication.
What affects carfilzomib patent expiry timing across EU countries?
Carfilzomib’s effective exclusivity window in Europe usually depends on several layers:
- The underlying European patent expiry date for the active substance and/or key claims.
- Any Supplementary Protection Certificate (SPC) granted to extend protection based on regulatory approval timing. SPCs can shift practical “market exclusivity” even if the main patent ends earlier.
- Patent families covering manufacturing processes, formulations, or specific uses (e.g., indications), which may expire at different times.
- Country-by-country enforcement: even within the EU/EEA, the ability to launch may hinge on which patents are in force and successfully challenged in each jurisdiction.
How long does an SPC typically extend protection in Europe?
SPCs can provide additional protection beyond the basic patent term, but their length is capped and tied to the timing of marketing authorisation and the rules set under EU law. The precise duration for a given product depends on the SPC decision for that product in each jurisdiction.
Can competitors launch in Europe before the patent/SPC expires?
Often, even if the active substance patent is still in force, generic/biosimilar entry may be possible only for parts of the claim space not covered by enforceable rights (or if rights are invalidated/waived). In practice, companies typically wait until:
- the relevant patents/SPCs expire, or
- a court decision removes the remaining enforceable protection, or
- they obtain a legal clearance for a specific product/indication and jurisdiction.
How to check the exact carfilzomib expiry date (practical route)
To get the correct date(s), the usual approach is to identify:
1) the specific product (brand),
2) the relevant active-ingredient/indication patents in the EPO/national registers, and
3) whether an SPC exists and its granted start/end dates in the countries of interest (for example, via EU SPC registers and national patent status).
If you tell me which EU country (e.g., UK, Germany, France, Italy, Spain, Netherlands) and whether you mean “patent expiry” or “market exclusivity/SPC expiry,” I can narrow down what to look for and how the dates typically map.
Sources
No sources were provided in the prompt, so I can’t cite specific expiry dates or legal documents.